|
|
| | KPT 251, >=98% Basic information |
| Product Name: | KPT 251, >=98% | | Synonyms: | KPT 251, >=98%;2-[(Z)-2-{3-[3,5-Bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl}vinyl]-1,3,4-oxadiazole;KPT251;AOB6639;SCHEMBL11318201;SCHEMBL11318201; AOB6639;;myeloid leukemia,Apoptosis,KPT 251,Chromosomal Maintenance 1,CRM1,inhibit,Exportin 1,KPT-251,melanoma,XPO1,A375,Inhibitor,antileukemic activity;1,3,4-Oxadiazole, 2-[(1Z)-2-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]ethenyl]- | | CAS: | 1388841-50-6 | | MF: | C14H7F6N5O | | MW: | 375.23 | | EINECS: | | | Product Categories: | | | Mol File: | 1388841-50-6.mol |  |
| | KPT 251, >=98% Chemical Properties |
| Boiling point | 417.9±55.0 °C(Predicted) | | density | 1.58±0.1 g/cm3(Predicted) | | form | Solid | | pka | -0.42±0.50(Predicted) | | color | Off-white to yellow |
| | KPT 251, >=98% Usage And Synthesis |
| Uses | KPT 251 is a novel CRM1 inhibitor, which has been shown to be effective in the treatment of acute myeloid leukemia. |
| | KPT 251, >=98% Preparation Products And Raw materials |
|